Pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Grifols has the lowest figure of the 50 pharmaceutical companies ranked by P/S ratio, at 0.7, followed by Viatris (1.7) and GSK (2.3). Figures as of 18 Nov 2026, 18:41 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- Lowest
- Grifols0.7
- Median
- 6.9
- Combined market value
- HUF 1709.74T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↑ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | GrifolsGRFS · Health Care | 0.7 | HUF 1.93T | HUF 2,841.84 | 1.91% down | 1% up | ||
| 2 | ViatrisVTRS · Health Care | 1.7 | HUF 7.95T | HUF 6,937.59 | 1.05% up | 96% up | ||
| 3 | GSKGSK · Health Care | 2.3 | HUF 32.85T | HUF 16,389.67 | 0.85% down | 6% up | ||
| 4 | SanofiSNY · Health Care | 2.3 | HUF 38.16T | HUF 15,892.84 | 0.40% down | 4% down | ||
| 5 | Takeda PharmaceuticalTAK · Health Care | 2.4 | HUF 22.95T | HUF 7,182.67 | 1.13% down | 54% up | ||
| 6 | Amneal PharmaceuticalsAMRX · Health Care | 2.6 | HUF 2.58T | HUF 7,417.67 | 4.62% up | 83% up | ||
| 7 | Bristol-Myers SquibbBMY · Health Care | 2.6 | HUF 41.32T | HUF 20,213.52 | 1.86% down | 34% up | ||
| 8 | PfizerPFE · Health Care | 2.6 | HUF 53.95T | HUF 9,465.54 | 0.97% down | 14% up | ||
| 9 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.9 | HUF 16.52T | HUF 14,155.51 | 1.07% down | 74% up | ||
| 10 | Elanco Animal HealthELAN · Health Care | 2.9 | HUF 4.52T | HUF 9,047.57 | 4.26% up | 20% up | ||
| 11 | PTC TherapeuticsPTCT · Health Care | 2.9 | HUF 1.69T | HUF 20,270.59 | 0.03% up | 20% down | ||
| 12 | Legend BiotechLEGN · Health Care | 3.1 | HUF 1.06T | HUF 5,452.04 | 0.81% up | 42% down | ||
| 13 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | HUF 4.21T | HUF 5,052.14 | 1.75% up | 5% up | ||
| 14 | BioMarin PharmaceuticalBMRN · Health Care | 3.6 | HUF 3.94T | HUF 20,336.06 | 3.53% up | 11% up | ||
| 15 | ZoetisZTS · Health Care | 3.7 | HUF 11.61T | HUF 28,584.62 | 1.99% up | 29% down | ||
| 16 | Jazz PharmaceuticalsJAZZ · Health Care | 3.7 | HUF 5.32T | HUF 82,950.50 | 2.65% up | 37% up | ||
| 17 | Novo NordiskNVO · Health Care | 3.8 | HUF 58.66T | HUF 13,309.50 | 2.59% down | 17% down | ||
| 18 | Abbott LaboratoriesABT · Health Care | 4.1 | HUF 60.77T | HUF 35,085.78 | 0.19% down | 17% down | ||
| 19 | AstraZenecaAZN · Health Care | 4.7 | HUF 93.57T | HUF 60,331.70 | 1.40% down | 2% up | ||
| 20 | Ionis PharmaceuticalsIONS · Health Care | 4.9 | HUF 1.56T | HUF 9,351.40 | 3.32% up | 64% down | ||
| 21 | Merck & CoMRK · Health Care | 5.3 | HUF 114.62T | HUF 46,494.05 | 3.40% down | 51% up | ||
| 22 | AlkermesALKS · Health Care | 5.3 | HUF 2.65T | HUF 15,771.98 | 3.37% up | 58% up | ||
| 23 | NovartisNVS · Health Care | 5.4 | HUF 98.94T | HUF 52,385.28 | 1.94% down | 25% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | HUF 6.79T | HUF 50,684.87 | 3.53% down | 66% down | ||
| 25 | Regeneron PharmaceuticalsREGN · Health Care | 6.8 | HUF 32.93T | HUF 318,300.00 | 1.01% down | 36% up | ||
| 26 | Johnson & JohnsonJNJ · Health Care | 7.0 | HUF 222.6T | HUF 92,469.86 | 1.17% down | 38% up | ||
| 27 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | HUF 2.06T | HUF 14,596.98 | 1.14% up | 10% up | ||
| 28 | United TherapeuticsUTHR · Health Care | 7.8 | HUF 8.33T | HUF 195,699.51 | 0.20% down | 23% up | ||
| 29 | AbbVieABBV · Health Care | 8.3 | HUF 170.67T | HUF 96,552.24 | 1.78% down | 26% up | ||
| 30 | GenmabGMAB · Health Care | 8.5 | HUF 10.66T | HUF 17,294.46 | 0.86% down | 70% up | ||
| 31 | BeOne MedicinesONC · Health Care | 8.7 | HUF 15.54T | HUF 136,056.03 | 1.93% down | 17% up | ||
| 32 | Corcept TherapeuticsCORT · Health Care | 9.8 | HUF 2.51T | HUF 22,926.11 | 2.54% down | 8% down | ||
| 33 | Madrigal PharmaceuticalsMDGL · Health Care | 9.9 | HUF 3.18T | HUF 137,014.50 | 3.29% down | 24% down | ||
| 34 | Travere TherapeuticsTVTX · Health Care | 10.0 | HUF 1.65T | HUF 17,188.71 | 0.20% up | 44% up | ||
| 35 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 11.1 | HUF 2.51T | HUF 32,003.90 | 0.23% up | 126% up | ||
| 36 | Axsome TherapeuticsAXSM · Health Care | 11.1 | HUF 2.38T | HUF 45,200.94 | 0.96% down | 7% down | ||
| 37 | Vertex PharmaceuticalsVRTX · Health Care | 11.4 | HUF 45.88T | HUF 180,956.50 | 0.90% up | 27% up | ||
| 38 | Mirum PharmaceuticalsMIRM · Health Care | 11.6 | HUF 2.03T | HUF 31,028.64 | 0.52% up | 31% up | ||
| 39 | TG TherapeuticsTGTX · Health Care | 16.2 | HUF 3.35T | HUF 22,185.86 | 5.38% up | 107% up | ||
| 40 | Royalty PharmaRPRX · Health Care | 16.8 | HUF 13.4T | HUF 23,305.47 | 1.08% up | 78% up | ||
| 41 | Eli LillyLLY · Health Care | 19.1 | HUF 417.4T | HUF 468,600.50 | 1.39% down | 35% up | ||
| 42 | Ascendis PharmaASND · Health Care | 22.3 | HUF 5.99T | HUF 91,271.38 | 0.25% up | 28% up | ||
| 43 | Ligand PharmaceuticalsLGND · Health Care | 22.4 | HUF 2.02T | HUF 100,992.07 | 2.39% up | 43% up | ||
| 44 | BridgeBio PharmaBBIO · Health Care | 30.3 | HUF 5.11T | HUF 26,243.00 | 1.78% up | 17% up | ||
| 45 | InsmedINSM · Health Care | 43.7 | HUF 8.89T | HUF 40,517.68 | 0.96% down | 40% down | ||
| 46 | Rhythm PharmaceuticalsRYTM · Health Care | 43.9 | HUF 2.79T | HUF 40,306.18 | 2.96% up | 13% up | ||
| 47 | CytokineticsCYTK · Health Care | 81.7 | HUF 2.42T | HUF 17,341.46 | 0.01% up | 20% down | ||
| 48 | Protagonist TherapeuticsPTGX · Health Care | 179 | HUF 2.76T | HUF 42,320.49 | 1.11% up | 46% up | ||
| 49 | Dianthus TherapeuticsDNTH · Health Care | 2418 | HUF 1.65T | HUF 29,348.38 | 0.51% up | 113% up | ||
| 50 | Roivant SciencesROIV · Health Care | 3382 | HUF 9.38T | HUF 12,945.25 | 0.39% down | 90% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 335.7 HUF). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies have the lowest P/S ratio?
Grifols (0.7), Viatris (1.7) and GSK (2.3) have the lowest P/S ratio of the 50 pharmaceutical companies ranked here as of 18 Nov 2026, 18:41 UTC.
How many pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 50 pharmaceutical companies ranked by P/S ratio have a combined market value of HUF 1709.74T as of 18 Nov 2026, 18:41 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.